Related Experiment Video
Updated: Jun 25, 2026
Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
Published on: April 25, 2016
Change in vasoactive inotropic score following hydrocortisone administration in the pediatric intensive care unit: a
Colin M Rogerson1,2, Stephanie R Brown3,4, Colleen Badke5,6
1Department of Pediatrics, Division of Critical Care Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.
Insights
Hydrocortisone (HCT) improved vasoactive inotropic score (VIS) in pediatric intensive care unit (PICU) patients with refractory hypotension. However, HCT did not show similar benefits in cardiovascular intensive care unit (CVICU) patients, indicating a need for further research.
Area of Science:
- Pediatric Critical Care Medicine
- Pediatric Pharmacology
- Pediatric Critical Care Research
Background:
- Hydrocortisone (HCT) is an ancillary therapy for pediatric refractory hypotension.
- Current guidelines for HCT use are non-specific due to limited evidence.
- Evaluating HCT's efficacy in pediatric intensive care units (PICUs) is crucial.
Purpose of the Study:
- To evaluate practice patterns of HCT use in PICU.
- To assess the association between HCT and vasoactive inotropic score (VIS) in critically ill children.
- To compare HCT's impact on VIS in PICU versus cardiovascular intensive care unit (CVICU) settings.
Main Methods:
- Retrospective observational cohort study using the PICU Data Collaborative (PDC).
- Included 10,244 pediatric encounters receiving vasoactive medications.
- Propensity score-matched comparison of VIS changes between HCT and control groups within the first 24 hours of ICU admission.
Main Results:
- 18.7% of encounters received HCT; these patients were older with higher maximum VIS.
- In the matched PICU cohort, HCT was associated with a greater decrease in VIS percentage from 24 to 48 hours (p=0.03).
- In the matched CVICU cohort, HCT was associated with higher initial VIS and smaller decreases in VIS percentage (p=0.01).
Conclusions:
- HCT use was linked to improved VIS in PICU patients but not in CVICU patients.
- Findings suggest HCT may benefit certain pediatric populations with refractory hypotension.
- Further research is needed to optimize patient selection and timing for HCT administration.
Objective:
Hydrocortisone (HCT) is an ancillary therapy for children with refractory hypotension. Current guidelines for HCT use are non-specific due to limited evidence of efficacy. We evaluated practice patterns and the association of HCT with the vasoactive inotropic score (VIS) in children admitted to the pediatric intensive care unit (PICU).
Materials And Methods:
This was a retrospective observational cohort study using the PICU Data Collaborative (PDC). Our cohort consisted of PDC encounters receiving at least one of the six vasoactive medications included in the VIS calculation (epinephrine, norepinephrine, dopamine, dobutamine, vasopressin, or milrinone). We calculated hourly VIS for the first 7 days of ICU admission. We conducted a propensity score-matched comparison of change in VIS from hours 24-48 between encounters receiving HCT within the first 24 h of ICU admission and controls who did not receive HCT.
Measurements And Main Results:
The cohort included 10,244 encounters from three institutions. Of these, 1,915 (18.7%) received HCT. Encounters receiving HCT were older [5.4 (0.8-13.8) years vs. 4.3 (0.6-13.3) years, respectively] and had a higher maximum VIS [15.0 (10.0-20.2) vs. 8.0 (5.0-13.0)]. The PICU cohort had a significantly greater decrease in VIS from 24 to 48 h after admission compared with the cardiovascular intensive care unit (CVICU) cohort [82.2% (-40% to 100%) vs. 16.2% (-4.0% to 100%); p < 0.01]. In the matched PICU cohort, there was no difference in the 24-h reference VIS; however, there was a greater decrease in percentage of VIS from the 24-h reference to 48 h for those who received HCT [100.0 (50.0-100.0) vs. 86.6 (0.0-100.0); p = 0.03]. In the matched CVICU cohort, the HCT group had a higher VIS at 24 h [7.7 (1.0-11.0) vs. 6.0 (0.0-10.0); p = 0.02], with smaller decreases in VIS percent from reference at 48 h [9.3 (-13.2 to 58.7) vs. 18.2 (0.0-80.0); p = 0.01].
Conclusions:
The use of HCT was associated with greater improvement in VIS between 24 and 48 h after admission for children in the PICU, but not for children in the CVICU. Further research is needed to determine the optimal patient selection and timing of HCT use.
More Related Videos
10:38Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies
Published on: January 16, 2019
11:06Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:29Drug Dosing: Infants and Children
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention